That Which Is Claimed:

1. Use of emricasan for preparation of a medicament for the treatment of a bacterial infection.

2. The use of claim 1, wherein the bacterial infection is a skin infection.

3. The use of claim 2, wherein the bacterial infection is a *Staphylococcus aureus* skin infection, a group A *Streptococcus* skin infection or a Pseudomonas aeruginosa skin infection.

4. The use of claim 3, wherein the bacterial infection is a *Staphylococcus aureus* skin infection.

5. The use of claim 4, wherein the bacterial infection is an antibiotic-resistant *Staphylococcus aureus* infection.

6. The use of claim 5, wherein the bacterial infection is a methicillin-resistant *Staphylococcus aureus* infection.

7. Use of emricasan for preparation of a medicament for the treatment of a skin and soft tissue bacterial infection.

8. The use of claim 7, wherein the skin and soft tissue bacterial infection is an antibiotic-resistant *Staphylococcus aureus* infection.

9. The use of claim 8, wherein the skin and soft tissue bacterial infection is a methicillin-resistant *Staphylococcus aureus* infection.

10. Use of a caspase inhibitor for preparation of a medicament for the treatment of a COVID-19 infection.

11. The use of claim 10, wherein the caspase inhibitor is a pan caspase inhibitor.

12. The use of claim 11, wherein the caspase inhibitor is emricasan.

13. Use of Q-VD-OPh for preparation of a medicament for the treatment of a bacterial infection.

14. The use of claim 13, wherein the bacterial infection is a *Staphylococcus aureus* skin infection, a group A *Streptococcus* skin infection or a Pseudomonas aeruginosa skin infection.

15. The use of claim 14, wherein the bacterial infection is a methicillin-resistant *Staphylococcus aureus* infection.

16. Use of Q-VD-OPh for preparation of a medicament for the treatment of a skin and soft tissue bacterial infection.

17. The use of claim 16, wherein the skin and soft tissue bacterial infection is a methicillin-resistant *Staphylococcus aureus* infection.

18. Use of Q-VD-OPh for preparation of a medicament for the treatment of a COVID-19 infection.